Effect of Bacteroides fragilis grown in the presence of clindamycin, metronidazole and fusidic acid on opsonization and killing of Escherichia coli.
Bactericidal action of human polymorphonuclear leucocytes on Escherichia coli in the presence of Bacteroides fragilis grown in subinhibitory concentrations of clindamycin, metronidazole and fusidic acid was studied. Bacteroides fragilis grown in the absence of drugs significantly inhibited the killing of Escherichia coli. Bacteroides fragilis grown in the presence of the drugs had a reduced inhibitory effect on the killing of Escherichia coli but this reduction was only significant for Bacteroides fragilis grown in 1/2 MIC of clindamycin. The phagocytosis of Bacteroides fragilis grown with and without clindamycin, as measured by killing, was the same. Complement consumption of Bacteroides fragilis grown with and without clindamycin did not differ. Clindamycin-treated Bacteroides fragilis fixed C3 to a significantly lower degree than did untreated bacteria. The chemiluminescence of Escherichia coli opsonized with serum preincubated with clindamycin-treated Bacteroides fragilis was significantly higher than with serum preincubated with untreated bacteria. These results suggested that in killing experiments of mixed Escherichia coli and Bacteroides fragilis, the mechanism underlying the reduced inhibitory capacity of clindamycin-exposed Bacteroides fragilis is related to greater availability of C3 in serum for opsonization of Escherichia coli.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001441:Bacteroides fragilis / Q000187:drug effects* / Q000502:physiology; D002981:Clindamycin / Q000494:pharmacology; D003176:Complement C3 / Q000276:immunology; D003168:Complement Fixation Tests; D003165:Complement System Proteins / Q000276:immunology; D004926:Escherichia coli / Q000276:immunology*; D005672:Fusidic Acid / Q000494:pharmacology; D006801:Humans; D008163:Luminescent Measurements; D008795:Metronidazole / Q000494:pharmacology; D009504:Neutrophils / Q000276:immunology*; D009895:Opsonin Proteins; D010587:Phagocytosis
D000900:Anti-Bacterial Agents; D003176:Complement C3; D009895:Opsonin Proteins; D008795:Metronidazole; D002981:Clindamycin; D005672:Fusidic Acid; D003165:Complement System Proteins